...
首页> 外文期刊>Stem Cells >Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
【24h】

Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.

机译:尿激酶纤溶酶原激活物和尿激酶纤溶酶原激活物介导人干细胞向恶性实体瘤的嗜性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Human neural and mesenchymal stem cells have been identified for cell-based therapies in regenerative medicine and as vehicles for delivering therapeutic agents to areas of injury and tumors. However, the signals required for homing and recruitment of stem cells to these sites are not well understood. Urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) are involved in chemotaxis and cell guidance during normal development and are upregulated in invasive tumors. Here we provided evidence that activation of uPA and uPAR in malignant solid tumors (brain, lung, prostate, and breast) augments neural and mesenchymal stem cell tropism. Expression levels of uPAR on human solid tumor cell lines correlated with levels of uPA and soluble uPAR in tumor cell-conditioned media. Cytokine expression profiles of these tumor-conditioned media were determined by protein arrays. Among 79 cytokines investigated, interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 were the most highly expressed cytokines in uPAR-positive tumors. We provided evidence that human recombinant uPA induced stem cell migration, whereas depletion of uPA from PC-3 prostate cancer cell-conditioned medium blocked stem cell migration. Furthermore, retrovirus-mediated overexpression of uPA and uPAR in neuroblastoma (NB1691) cells induced robust migration of stem cells toward NB1691 cell-conditioned media, compared with media derived from wild-type NB1691 cells. We conclude that expression of uPA and uPAR in cancer cells underlies a novel mechanism of stem cell tropism to malignant solid tumors, which may be important for development of optimal stem cell-based therapies. Disclosure of potential conflicts of interest is found at the end of this article.
机译:人类神经和间充质干细胞已被确定为再生医学中基于细胞的疗法,并已成为将治疗剂输送至损伤和肿瘤区域的载体。然而,将干细胞归巢和募集到这些位点所需的信号还不是很清楚。尿激酶纤溶酶原激活物(uPA)和尿激酶纤溶酶原激活物受体(uPAR)在正常发育过程中参与趋化性和细胞指导,并在浸润性肿瘤中上调。在这里,我们提供了证据,表明在恶性实体瘤(脑,肺,前列腺和乳腺)中uPA和uPAR的激活会增强神经和间充质干细胞的嗜性。人实体肿瘤细胞系上uPAR的表达水平与肿瘤细胞条件培养基中uPA和可溶性uPAR的水平相关。这些肿瘤条件培养基的细胞因子表达谱通过蛋白质阵列确定。在调查的79种细胞因子中,白细胞介素(IL)-6,IL-8和单核细胞趋化蛋白1是uPAR阳性肿瘤中表达最高的细胞因子。我们提供的证据表明,人重组uPA诱导干细胞迁移,而PC-3前列腺癌细胞条件培养基中uPA的消耗阻止了干细胞迁移。此外,与衍生自野生型NB1691细胞的培养基相比,逆转录病毒介导的神经母细胞瘤(NB1691)细胞中uPA和uPAR的过表达诱导干细胞向NB1691细胞条件培养基的强劲迁移。我们得出的结论是,uPA和uPAR在癌细胞中的表达是干细胞向恶性实体瘤趋向的新机制,这对于开发基于干细胞的最佳疗法可能很重要。在本文的末尾发现了潜在的利益冲突。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号